PRLD Prelude Therapeutics Incorporated

Prelude is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small molecule therapies that target key drivers of cancer cell growth, survival and resistance.

$14.00  -0.31 (-2.17%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/25/2020
Outstanding shares:  47,215,352
Average volume:  235,351
Market cap:   $675,651,687
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    74065P101
ISIN:        US74065P1012
Sedol:      BKX8YL9
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.08
PS ratio:   0.00
Return on equity:   -31.52%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy